OS Therapies has secured full alignment with the UK MHRA and European EMA on its Conditional Marketing Authorisation Application (CMAA) for its gene-edited cancer immunotherapy OST-HER2 targeting metastatic osteosarcoma. The regulators agreed on using historical control data and the Phase 3 trial design, which OS Therapies plans to start in Q4 2026. The company aims to submit the CMAA soon and is also pursuing FDA approval under the Accelerated Approval Program, potentially gaining early market access and a Priority Review Voucher. This regulatory progress marks a significant step toward commercializing OST-HER2, which has shown promising Phase 2 results in preventing recurrence of osteosarcoma.
OS Therapies' regulatory progress is noted here alongside Pluang's market data for health stocks. For readers following health stocks, here is Pluang's market snapshot as of Sep 15, 2026 18:13 WIB: out of 91 priced US health stocks, 31 rose and 54 fell. Notable movers include ASND at USD 258.00 (-2.61%), INO at USD 1.21 (+2.54%), and DNA at USD 6.86 (-2.14%).
Aerie, developed by LayerZero Labs and partners, aggregates 32,768 post-quantum signatures in just 0.65 seconds using a MacBook Pro without specialized hardware. It outperforms previous systems by generating and verifying proofs faster and producing ...
Bitcoin has experienced a 25% decline over the past year but continues to show long-term momentum, according to Charles Schwab analyst Adam Lynch. Despite this pullback, cumulative net inflows into U.S. spot Bitcoin ETFs have reached nearly $57 billi...
Digital-asset treasury companies collectively hold an estimated 1.073 million Bitcoin (BTC), with Strategy holding the largest share at 848,500 BTC. This estimate slightly exceeds Strategy's last disclosed balance by 250 BTC, reflecting recent purcha...
Zcash (ZEC) experienced a sharp price decline of 4.62% within four hours, falling from $1,228 to $1,171 on October 16. This drop was significantly steeper than the 1.48% decrease observed over the past 24 hours, indicating increased short-term sellin...
Venice Token (VVV) rose 10% in 24 hours after successfully bouncing off the $21 support level, which was previously a resistance barrier. This surge follows the launch of new AI-powered products and strong revenue growth, especially in October. The $...
